Drugs / CD20 CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04169932 | Nov 2019 → Nov 2022 | B-cell non-Hodgkin lymphoma | Shanghai Longyao Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05618041 | Sep 2022 → Sep 2027 expected | acute lymphoblastic leukemia, plasma cell myeloma | Hebei Senlang Biotechnology Inc., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD20 CAR-T | “CD20 CAR-T” NCT05618041 ↗ |
| Modality | Cell therapy | “CD20 CAR-T Cells” NCT04169932 ↗ |
| Route | Intravenous | “Subjects receive a single intravenous infusion of CD20-CART cells per treatment course.” NCT04169932 ↗ |